Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Baxter
McKesson

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,722,640

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,722,640
Title:Stabilized STAT3 decoy oligonucleotides and uses therefor
Abstract: The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer.
Inventor(s): Grandis; Jennifer R. (Pittsburgh, PA), Johnson; Daniel (Glenshaw, PA), Ly; Danith (Pittsburgh, PA)
Assignee: UNiversity of Pittsburgh - of the Commonwealth System of Higher Education (N/A)
Application Number:13/491,343
Patent Claims:1. A cyclic double-stranded STAT3 oligonucleotide decoy, wherein (i) the decoy comprises an oligonucleotide, or an analog thereof, having the sequence 5'-(N.sub.6-).sub.nCAN.sub.1TTCN.sub.2CN.sub.3TN.sub.4AN.sub.5TC- -(N.sub.7-).sub.m-3', (SEQ ID NO:1), wherein N.sub.3 is G; N.sub.1, N.sub.2, N.sub.4 and N.sub.5 are A, T, G or C; one, two, three or all of the following conditions are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A; and N.sub.6 and N.sub.7 are A, T, G or C and n and m are independently 0-50; (ii) the two strands are joined by hexa-ethyleneglycol spacers at both ends; (iii) the decoy binds to STAT3 protein under physiologic conditions and interferes with STAT3 binding to its target sequence; and (iv) the decoy has a serum half-life of greater than about 4 hours.

2. The STAT3 oligonucleotide decoy of claim 1, wherein the oligonucleotide comprises the sequence 5'-CATTTCCCGTAAATC-3' (SEQ ID NO:30).

3. The STAT3 oligonucleotide decoy of claim 1, wherein N.sub.2 is a pyrimidine.

4. The STAT3 oligonucleotide decoy of claim 1, wherein at least two of the following are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A.

5. The STAT3 oligonucleotide decoy of claim 1, wherein at least three of the following are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a cyclic double-stranded STAT3 oligonucleotide decoy, wherein (i) the decoy comprises an oligonucleotide, or an analog thereof, having the sequence 5'-(N.sub.6-).sub.nCAN.sub.1TTCN.sub.2CN.sub.3TN.sub.4AN.sub.5TC-(N.sub.7- -).sub.m-3', (SEQ ID NO:1), wherein N.sub.3 is G; N.sub.1, N.sub.2, N.sub.4 and N.sub.5 are A, T, G or C; one, two, three or all of the following conditions are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A; and N.sub.6 and N.sub.7 are A, T, G or C and n and m are independently 0-50; (ii) the two strands are joined by hexa-ethyleneglycol spacers at both ends; (iii) the decoy binds to STAT3 protein under physiologic conditions and interferes with STAT3 binding to its target sequence; and (iv) the decoy has a serum half-life of greater than about 4 hours.

7. The pharmaceutical composition of claim 6, further comprising an anticancer agent.

8. The composition of claim 6, formulated as a parenteral dosage form.

9. The composition of claim 8, formulated as an intravenous dosage form.

10. The composition of claim 6, wherein the decoy is contained within a microbubble.

11. The composition of claim 6, wherein the decoy is associated with a peptide transduction domain.

12. The composition of claim 11, wherein the peptide transduction domain is TAT.

13. A method of inhibiting growth of a cancer in which STAT3 is activated in a patient, comprising administering to the patient an amount of a cyclic double-stranded STAT3 oligonucleotide decoy effective to inhibit growth of a cancer in a patient, thereby inhibiting growth of the cancer in the patient; wherein (i) the oligonucleotide decoy comprises an oligonucleotide having the sequence 5'-(N.sub.6-).sub.nCAN.sub.1TTCN.sub.2CN.sub.3TN.sub.4AN.sub.5TC-(N.sub.7- -).sub.m-3', (SEQ ID NO: 1), wherein N.sub.3 is G; N.sub.1, N.sub.2, N.sub.4 and N.sub.5 are A, T, G or C; one, two, three or all of the following conditions are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A; and N.sub.6 and N.sub.7 are A, T, or C and n and m are independently 0-50; (ii) the two strands are joined by hexa-ethyleneglycol spacers at both ends; (iii) the decoy binds to STAT3 protein under physiologic conditions and interferes with STAT3 binding to its target sequence; and (iv) the decoy has a serum half-life of greater than about 4 hours.

14. The method of claim 13, wherein the cancer is a squamous cell carcinoma.

15. The method of claim 14, wherein the cancer is a squamous cell carcinoma of the head and neck.

16. The method of claim 13, comprising administering to the patient a second anticancer therapy.

17. The method of claim 16, wherein the second anticancer therapy is one or both of a radiation therapy and treating the patient with an anticancer agent.

18. The method of claim 16, wherein the second anticancer therapy is a radiation therapy.

19. The method of claim 16, wherein the second anticancer therapy comprises treating the patient with an anticancer agent.

20. The methods of claim 16, wherein the anticancer therapy is an epidermal growth factor receptor (EGFR) antagonist.

21. The method of claim 20, wherein the epidermal growth factor receptor (EGFR) antagonist is cetuximab.

22. The method of claim 13, wherein the cancer is selected from the group consisting of multiple myeloma, HTLV-1 dependent leukemia, acute myelogenous leukemia, large granular lymphocyte leukemia, lymphoma, EBV-related Burkitt's lymphoma, mycosis fungoides, cutaneous T-cell lymphoma, non-Hodgkins lymphoma, anaplastic large-cell lymphoma, breast cancer, melanoma, ovarian cancer, lung cancer, pancreatic cancer, and prostate cancer.

23. The method of claim 13, wherein the STAT3 oligonucleotide decoy comprises the sequence 5'CATTTCCCGTAAATC-3' (SEQ ID NO:30).

24. The method of claim 13, wherein, in the STAT3 oligonucleotide decoy, N.sub.2 is a pyrimidine.

25. The method of claim 13, wherein, in the STAT3 oligonucleotide decoy, at least two of the following are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A.

26. The method of claim 13, wherein, in the STAT3 oligonucleotide decoy, at least three of the following are met: N.sub.1, is T; N.sub.2 is C; N.sub.4 is A and N.sub.5 is A.

27. The method of claim 13, wherein the STATS oligonucleotide decoy comprises a 15-mer oligonucleotide 5'-CATTTCCCGTAAATC-3' (SEQ ID NO:30) joined at both ends by hexa-ethyleneglycol spacers.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Merck
Harvard Business School
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.